Patent ID: 6476028
Filing Date: 2002-11-05
Classification: A61K,A61P,C07D

Abstract:
A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein:X is hydrogen or one or more of C1-6alkyl, CONRRâ€², trifluoromethyl, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo where R and Râ€² are independently hydrogen or C1-6alkyl; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; the dotted line, . . . , indicates a single bond or a double bond; R3 is hydrogen or C1-6alkyl; A is [C(Râ€³)2]m CRâ€³R4R5 or [C(Râ€³)2]nCRâ€³=C R4R5 where each Râ€³ is independently hydrogen or C1-6alkyl; m is 0-3; n is 1-2 R4 is phenyl, biphenyl, naphthyl, 1-benzotriazinyl, or 2-benzotriazinyl, optionally substituted with one or more of C1-6alkyl, cyano, trifluoromethyl, NR6R7, nitro, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo, where R6 and R7 are independently hydrogen or C1-6alkyl; R5 is Râ€² when m is 0; alternatively, R5 is Râ€³, phenyl or naphthyl when m is 1-3 or n is 1-2, wherein phenyl or naphthyl are optionally substituted with one or more of C1-6alkyl, cyano, trifluoromethyl, NR6R7, nitro, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo.